4.2.2.3Vertical
Medication-Assisted Treatment (MAT)
Programs using buprenorphine, methadone, or naltrexone for addiction treatment.
Market snapshot
These figures describe Addiction & Substance Use Treatment (4.2.2), the segment that Medication-Assisted Treatment (MAT) sits within — not Medication-Assisted Treatment (MAT) on its own.
FragmentationConsolidatingEstimate
No single discrete Census NAICS code — addiction treatment spans outpatient centers (621420), residential (623220), and hospitals (622210), so the segment is not separately sized by the Census Bureau.
Business model & economics
Revenue model
Per-diem residential, outpatient, and MAT reimbursement
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 12–22%
- Capex intensity
- Moderate
recurring MAT and outpatient care
Characteristics
- Demand driven by the opioid and addiction crisis.
- MAT expanded evidence-based, recurring treatment.
- Fraught history of scandals and quality concerns.
M&A deal context
Deal activityHigh
Who’s acquiring
- PE-backed treatment platforms
- MAT and outpatient consolidators
- Behavioral-health operators
What’s driving deals
- Consolidation of treatment providers.
- Opioid-crisis and addiction demand.
- Regulatory and reputational scrutiny.
Find Medication-Assisted Treatment (MAT) acquisition targets
Search Acquisera’s index for companies classified under Medication-Assisted Treatment (MAT) (4.2.2.3) and build a targeted deal pipeline.
Search companies